DMK Pharmaceuticals Corp
OTC:DMKPQ
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
DMK Pharmaceuticals Corp
OTC:DMKPQ
|
US |
|
Energy World Corporation Ltd
ASX:EWC
|
AU |
|
TotalEnergies SE
PAR:TTE
|
FR |
|
Sinotruk Jinan Truck Co Ltd
SZSE:000951
|
CN |
|
NWF Group PLC
LSE:NWF
|
UK |
|
A
|
Avino Silver & Gold Mines Ltd
AMEX:ASM
|
CA |
|
My Size Inc
NASDAQ:MYSZ
|
IL |
|
N
|
Nextleaf Solutions Ltd
CNSX:OILS
|
CA |
|
Senetas Corp Ltd
ASX:SEN
|
AU |
|
L
|
Lion Rock Resources Inc
XTSX:ROAR
|
CA |
|
AK Holdings Inc
KRX:006840
|
KR |
|
Marten Transport Ltd
NASDAQ:MRTN
|
US |
|
Selvaag Bolig ASA
OSE:SBO
|
NO |
|
Novatti Group Ltd
ASX:NOV
|
AU |
|
M
|
Myoung Shin Industrial Co Ltd
KRX:009900
|
KR |
DMK Pharmaceuticals Corp
Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company is headquartered in San Diego, California and currently employs 11 full-time employees. The firm is focused on developing therapies for opioid use disorder (OUD) and other neuro-based conditions. The Company’s commercial products approved by the United States Food and Drug Administration (FDA) include ZIMHI (naloxone) injection for the treatment of opioid overdose, and SYMJEPI (epinephrine) Injection for use in the emergency treatment of acute allergic reactions, including anaphylaxis. The company has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline. The Company’s lead clinical-stage product candidate, DPI-125, is being studied as a treatment for OUD. The Company’s other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinson’s disease.
Adamis Pharmaceuticals Corp. is a biopharmaceutical company, which engages in the discovery, development, and sale of pharmaceutical, specialty biopharmaceutical, and other drug products. The company is headquartered in San Diego, California and currently employs 11 full-time employees. The firm is focused on developing therapies for opioid use disorder (OUD) and other neuro-based conditions. The Company’s commercial products approved by the United States Food and Drug Administration (FDA) include ZIMHI (naloxone) injection for the treatment of opioid overdose, and SYMJEPI (epinephrine) Injection for use in the emergency treatment of acute allergic reactions, including anaphylaxis. The company has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline. The Company’s lead clinical-stage product candidate, DPI-125, is being studied as a treatment for OUD. The Company’s other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinson’s disease.
